Clinics and Research in Hepatology and Gastroenterology
Original articleHER2/neu over-expression predicts poor outcome in early gastric cancer without lymph node metastasis
Introduction
Gastric cancer (GC) is still a problem of human health all over the world. Despite its incidence rate decreases globally, GC is the fourth most common cancer [1], [2]. Early gastric cancer (EGC) is defined as gastric cancer confined to the mucosa and submucosa of the stomach, with/without lymph node metastasis. In recent years, a high participation rate for endoscopic screening has shown that EGC accounts for almost half of all GC [3], [4]. The high cure rate of EGC and the low frequency of perigastric lymph node metastases have allowed the development of more limited modified procedure that improve patient quality of life without compromising cure rate [5], [6].
Human epidermal growth factor receptor 2 (HER2/neu) is a proto-oncogene encoded by ERBB2 on chromosome 17. The role of HER2/neu is to inhibit cell apoptosis and promote proliferation. This may lead to excessive or uncontrolled cell growth and may cause tumorigenesis [7], [8]. Advances in the molecular biology, genomics and proteomics have led to better understanding of the role for HER2/neu. HER2/neu is closely associated with several malignant forms of cancer, notably GC. Anti-HER2/neu antibody trastuzumab has been approved for the treatment of gastric cancer after a successful phase III trial (ToGA) which demonstrated improved survival for HER2/neu-positive advanced GC patients [9]. HER2/neu were connected to both poor outcomes and higher recurrence in breast cancer [10], [11], [12]. Studies even have demonstrated trastuzumab was effective against early breast cancer [13], [14], [15]. However, the value of HER2/neu serve as a prognosis factor in EGC remains unclear. Therefore, the aim of this study was to analyze whether the over-expression of HER2/neu amplification significantly predicts poor outcomes of EGC without lymph node metastasis.
Section snippets
Patients
We chose all patients with EGC who were confirmed between January 2000 and December 2008 by postoperative pathology to have no lymph node metastasis at Tianjin Medical University General Hospital, Tianjin, China. Only patients with gastric cancer confined to the mucosa and submucosa were finally included. Oncological assessment was performed every six months to each patient, and these patients were followed up by phone calls or mail for the status of survival. There were a total of 67
IHC
Anti-HER2/neu (4b5) antibody (Ventana Medical Systems, Inc. Tucson, Arizona) was used to carry IHC staining as the primary antibody against HER2/neu on an automatic immmunostainer (Benchmark XT, Ventana Medical Systems Inc. Tucson, Arizona) according to the manufacturer's instructions.
By following the National Comprehensive Cancer Network (NCCN) guideline, a semiquantitative approach was used to generate a score for each case as follows: no membrane staining or membrane staining in less than
FISH
In IHC 2+ patients, The PathVysion®HER2 DNA Probe kit (LSI®HER2/neu Spectrum OrangeTM/CEP®17 Spectrum GreenTM) was used to carry out FISH analysis according to the manufacturer's protocol to detect HER2/neu amplification levels. FISH positive was defined as HER2/neu: CEP17 ratio≥2. IHC 2+ patients would be considered HER2/neu-positive only if they are FISH+.
Statistical analysis methods
The Chi2 test and Krushal-Wallis test were carried out to compare the relationship between the HER2/neu status and clinicopathological factors. Overall survival was calculated using the Kaplan-Meier method, and differences between survival rates were analyzed with the long-rank test. The Cox proportional hazard model was used for multivariate analysis. Results were considered significant when P values were less than 0.05. Statistical analyses were performed using SPSS-19 (IBM SPSS Statistics,
Patients and tumor characteristics
Between January 2000 and December 2008 a total of 67 patients underwent curative-intent surgery for EGC and were successfully followed up. The patient characteristics are summarized in Table 1. The patients had an average age of 57.3 years and 43 of them were male, with follow numbers of different Lauren's tumor types (intestinal: 61.2%; diffuse: 17.9%; mixed: 20.9%). In terms of tumor location, 32.8% of the 67 tumors located at the gastroesophageal junction, 13.4%, 7.5%, 46.3% located at
Discussion
HER2/neu belongs to the HER family which is composed of four plasma membrane-bound receptor tyrosine kinases. This tyrosine kinase contributes to signal transduction via different pathways, for instance mitogen-activated protein kinase, phosphoinositide 3-kinase, phospholipase C and protein kinase C. Many studies have showed [16], [17] that HER2/neu is expressed in various tissues, including the heart, kidney, gastrointestinal tract and breast. HER2/neu predicts very poor outcome in breast
Disclosure of interest
The authors declare that they have no conflicts of interest concerning this article.
References (26)
- et al.
The management of early gastric cancer
Surgical oncology
(2000) - et al.
The role of over expressed her2 in transformation
Annals of oncology: official journal of the European Society for Medical Oncology/ESMO
(2001) - et al.
Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of her2-positive advanced gastric or gastro-oesophageal junction cancer (toga): a phase 3, open-label, randomised controlled trial
Lancet
(2010) - et al.
Adjuvant trastuzumab for her2-positive breast cancer
Lancet
(2005) - et al.
Amplification of her-2 in gastric carcinoma: association with topoisomerase iialpha gene amplification, intestinal type, poor prognosis and sensitivity to trastuzumab
Annals of oncology: official journal of the European Society for Medical Oncology/ESMO
(2005) - et al.
Effect of her2 on prognosis and benefit from peri-operative chemotherapy in early oesophago-gastric adenocarcinoma in the magic trial
Annals of oncology: official journal of the European Society for Medical Oncology/ESMO
(2013) - et al.
Global patterns of cancer incidence and mortality rates and trends. Cancer epidemiology, biomarkers & prevention: a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology
Cancer epidemiology biomarkers and prevention
(2010) - et al.
Global cancer statistics
CA: a cancer journal for clinicians
(2011) - et al.
Gastric cancer treatment in Japan: 2008 annual report of the jgca nationwide registry
Gastric cancer: official journal of the International Gastric Cancer Association and the Japanese Gastric Cancer Association
(2011) - et al.
Prospective study of proximal gastrectomy for early gastric cancer in the upper third of the stomach
The British journal of surgery
(2003)
Medium- and long-term results of jejunal pouch reconstruction after a total and proximal gastrectomy
Surgery today
Biologic and therapeutic role of her2 in cancer
Oncogene
Prognostic significance of her-2 oncoprotein expression in breast cancer: a 30-year follow-up
Journal of clinical oncology: official journal of the American Society of Clinical Oncology
Cited by (15)
Liver metastases from gastric carcinoma: A Case report and review of the literature
2017, Current Problems in CancerCitation Excerpt :Although tremendous progress has been made in the molecular typing of gastric cancer, predictive markers for aggressive treatment of metastatic disease has yet to be defined.40 The HER2 overexpression is independent prognostic factor for poor outcome even in early gastric cancer without lymph node metastases.41 Conversion of HER2 expression between primary tumor and lymph node metastasis is an independent risk factor for shorter OS.42
Noninvasive Assessment of HER2 Expression Status in Gastric Cancer Using <sup>18</sup>F-FDG Positron Emission Tomography/Computed Tomography-Based Radiomics: A Pilot Study
2024, Cancer Biotherapy and Radiopharmaceuticals